Pharma Equity Group A/S Stock

Pharma Equity Group A/S Equity

The The Equity of Pharma Equity Group A/S (PEG.CO) as of Aug 15, 2026 is 25.47 M DKK. In the previous year, The Equity was 48.88 M DKK — a change of -47.88% (lower).

Equity

25.47 MDKK

YoY

-47.88%

Last updated:

In 2026, Pharma Equity Group A/S's equity was 25.47 M DKK, a -47.88% increase from the 48.88 M DKK equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Pharma Equity Group A/S Stock analysis

What does Pharma Equity Group A/S do? Blue Vision A/S is a company specializing in the development, production, and marketing of underwater technology. It was founded in 1992 and is headquartered in Holstebro, Denmark. The company focuses on underwater lighting, underwater inspection cameras, and underwater communication. It specializes in manufacturing underwater lighting products for the offshore industry, ports, and shipping. It also produces underwater inspection cameras for inspecting underwater structures without the need for divers. In addition, the company has developed devices for underwater communication, which are crucial in the offshore industry and military sector. Blue Vision A/S emphasizes innovation and technology, holding patents and investing in digital technology to improve inspection systems. In summary, Blue Vision A/S specializes in underwater technology and offers solutions for the offshore industry, ports, and shipping. The company is committed to innovation and technology to provide the best solutions to its customers. Pharma Equity Group A/S is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Pharma Equity Group A/S's Equity

Pharma Equity Group A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Pharma Equity Group A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Pharma Equity Group A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Pharma Equity Group A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Pharma Equity Group A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Pharma Equity Group A/S stock

The Equity of Pharma Equity Group A/S is 25.47 M DKK in 2026.

The Equity of Pharma Equity Group A/S changed from 48.88 M DKK to 25.47 M DKK, representing a -47.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Pharma Equity Group A/S since 2006 – with annual values, charts, and detailed analysis.

The Equity's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Pharma Equity Group A/S historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Pharma Equity Group A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Pharma Equity Group A/S